Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, April 19, 2022
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
[ Tue, Apr 19th 2022
] - WOPRAI
Graig Suvannavejh Maintained (TGTX) at Strong Sell with Decreased Target to $5 on, Apr 19th, 2022
Graig Suvannavejh of Goldman Sachs, Maintained "TG Therapeutics, Inc." (TGTX) at Strong Sell with Decreased Target from $8 to $5 on, Apr 19th, 2022.
Graig has made no other calls on TGTX in the last 4 months.
There is 1 other peer that has a rating on TGTX. Out of the 1 peers that are also analyzing TGTX, 0 agree with Graig's Rating of Hold.
This is the rating of the analyst that currently disagrees with Graig
- Edward White of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $19 on, Monday, April 18th, 2022
